secwatch.observer — SEC 8-K summary
======================================

Issuer:     CytomX Therapeutics, Inc. (CTMX)
CIK:        0001501989
Form:       8-K
Filed at:   2025-08-13T23:59:59+00:00
Accession:  0001193125-25-179463
Event type: other_material
Sentiment:  negative
Materiality: 0.75
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

CytomX reports Grade 5 adverse event in CX-2051 Phase 1 trial; FDA notified, study continues
--------------------------------------------------------------------------------

- Single Grade 5 acute kidney injury occurred in patient with solitary kidney; event believed secondary to nausea, vomiting, diarrhea.
- Safety Review Committee convened July 14, 2025, supported continued study execution and enrollment.
- FDA notified on July 18, 2025; company aware on July 11, 2025.
- CX-2051 dose expansions at 7.2, 8.6, and 10 mg/kg each enrolled ~20 patients as planned.
- Phase 1 data update expected by Q1 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1501989/000119312525179463/0001193125-25-179463-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1501989/000119312525179463/d925542d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-179463

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer